The Quantellect read.As of Nov 19, 2026, 5 active firms cover Immunitybio Inc: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $12.00 to $23.00, a moderate spread. The average target of $16.00 sits 138% above the current $6.71. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.08 next quarter toward $-0.36 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$16.00
+138.4% upside
Average target across 4 active firms as of Nov 19, 2026 vs $6.71 current
Highest Target$23.00
Average Target$16.00
Lowest Target$12.00
Detailed analyst forecasts for IBRX
Showing 1–4 of 4 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate IBRX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IBRX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.08 – $-0.08 · 1 analysts · -5% YoY
Next period, 1 analysts expect Immunitybio Inc to earn $-0.08 a share (range $-0.08 – $-0.08), versus $-0.08 a year earlier. Full-year consensus is $-0.93, growing to $-0.36 the year after.
REVENUE · NEXT QUARTER
$68.9M
Range $67.3M – $70.2M · 1 analysts · +56% YoY
Revenue is expected to reach $68.9M (range $67.3M – $70.2M), +55.9% year-over-year. Full-year consensus is $201.8M, rising to $351.5M next year.
Top analysts covering Immunitybio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IBRX.
#1
Andres Y. Maldonado
HC Wainwright & Co. · Rank #288
Buy
$15.00+123.5% to target
Overall win rate
39%
+ Follow
#2
Edward Tenthoff
Piper Sandler · Rank #460
Buy
$12.00+78.8% to target
Overall win rate
29%
+ Follow
#3
Jason Kolbert
D. Boral Capital · Rank #562
Buy
$23.00+242.6% to target
Overall win rate
22%
+ Follow
#4
JM
Jeet Mukherjee
BTIG
Buy
$12.00+78.8% to target
Coverage
—
+ Follow
#5
KS
Kelly Shi
Jefferies
Buy
$14.00+108.6% to target
Coverage
—
+ Follow
IBRX stock forecast FAQ
What is IBRX's average 12-month price target?+
The 4 active firms with a live target average $16.00 for Immunitybio Inc over the next 12 months, ranging from a $23.00 high to a $12.00 low, as of Nov 19, 2026.
Is IBRX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for IBRX?+
The Street-high target is $23.00 (D. Boral Capital), and the Street-low is $12.00 (BTIG). The average of all 4 active-firm targets is $16.00.
How many active Wall Street firms cover IBRX?+
5 active firms have a recognized rating on Immunitybio Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IBRX?+
Among analysts who currently cover IBRX, Andres Y. Maldonado of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #288). Their current call is Buy with a $15.00 target.
What is Immunitybio Inc's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.08 – $-0.08) across 1 analysts. Full-year EPS is projected at $-0.93, rising to $-0.36 the following year.
How much revenue is Immunitybio Inc expected to report next quarter?+
Consensus revenue is $68.9M (range $67.3M – $70.2M). Full-year revenue is projected at $201.8M, growing to $351.5M next year.
Have analysts been upgrading or downgrading IBRX lately?+
As of Nov 19, 2026, 5 of 5 active firms rate IBRX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IBRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.